Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.

ABSTRACT: Retinal vein occlusions (RVOs) constitute the second most common cause of retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% in persons older than 40 years of age. Despite the existence of numerous potential therapeutic options, none is entirely satisfactory, and many patients with RVO suffer irreversible visual loss. Fortunately however, the recent introduction of antivascular endothelial growth factor (VEGF) agents, such as ranibizumab (Lucentis(®), Genentech, South San Francisco, CA) and bevacizumab (Avastin(®), Genentech), offers a potentially new treatment approach for clinicians managing this disorder. The results of the BRAVO and CRUISE trials have provided the first definitive evidence for the efficacy and safety of ranibizumab in the treatm

SUBMITTER: Keane PA 

PROVIDER: S-EPMC3130914 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature